Quince Therapeutics Inc.

NASDAQ: QNCX · Real-Time Price · USD
1.70
0.02 (1.19%)
At close: Aug 15, 2025, 3:59 PM
1.62
-4.71%
After-hours: Aug 15, 2025, 07:43 PM EDT

Quince Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
168K 168K 168K 36K 36K 36K 36K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
202K 246K 254K 474K 388K 345K 322K 60K 100K 183K 204K 246K 293K 296K 344K 260K 173K 86K
Gross Profit
-34K -78K -86K -438K -352K -309K -286K -60K -100K -183K -204K -246K -293K -296K -344K -260K -173K -86K
Operating Income
-43.16M -60.92M -57.28M -53.62M -53.85M -31.24M -32.98M -30.95M -32.48M -43.15M -52.06M -69.28M -83.34M -88.87M -90.32M -87.63M -87.86M -84.35M
Interest Income
1.94M 2.45M 2.93M 3.41M 3.68M 3.67M 3.48M 3M 2.36M 1.7M 1.07M 637K 450K 465K 620K 812K 1.09M 1.59M
Pretax Income
-48.9M -60.61M -56.74M -53.13M -53.01M -30.2M -31.58M -28.27M -30.84M -42.8M -51.94M -69.81M -83.59M -88.5M -89.94M -87.1M -86.9M -82.76M
Net Income
-49.03M -60.71M -56.83M -53.26M -53.12M -30.28M -31.39M -28.31M -31.18M -42.86M -52.02M -69.6M -83.09M -88.28M -89.94M -87.1M -86.9M -82.76M
Selling & General & Admin
16.05M 17.4M 15.24M 15.56M 16.59M 16.13M 17.32M 16.27M 15.95M 20.78M 26.06M 30.84M 34.13M 32.14M 29.52M 26.19M 23.48M 20.6M
Research & Development
25.44M 23.03M 18.39M 16M 12.51M 9.72M 9.45M 8.78M 9.8M 15.65M 25.18M 37.62M 49.21M 56.73M 60.79M 61.44M 64.38M 63.75M
Other Expenses
1.68M 20.49M 18.57M 18.55M 21.23M 1.88M 1.88M n/a n/a n/a 150K 190K 33K -98K -248K -288K -131K n/a
Operating Expenses
43.16M 60.92M 52.2M 50.11M 50.34M 27.73M 28.66M 25.05M 25.75M 36.43M 51.23M 68.46M 83.34M 88.87M 90.32M 87.63M 87.86M 84.35M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a -2.34M -2.64M -2.64M -2.64M -304K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
32.73M 60.92M 57.28M 55.19M 55.42M 32.82M 28.66M 25.05M 25.75M 36.43M 51.23M 68.46M 83.34M 88.87M 90.32M 87.63M 87.86M 84.35M
Income Tax Expense
-94K 9K 87K 131K 118K 82K -197K 36K 337K 53K 79K -205K -477K -222K -227K -227K -256K -227K
Shares Outstanding (Basic)
46.69M 43.94M 43.26M 43.16M 43.1M 43.01M 40.97M 36.07M 35.92M 35.86M 36.14M 35.61M 32.47M 30.13M 29.77M 29.77M 29.59M 29.55M
Shares Outstanding (Diluted)
46.69M 43.94M 43.26M 43.16M 43.1M 43.01M 40.97M 36.07M 35.92M 35.86M 36.14M 35.61M 32.47M 30.13M 29.77M 29.77M 29.59M 29.55M
EPS (Basic)
-1.09 -1.39 -1.31 -1.25 -1.27 -0.77 -0.85 -0.79 -0.87 -1.24 -1.61 -2.24 -2.74 -2.97 -3.04 -2.95 -2.95 -2.81
EPS (Diluted)
-1.09 -1.39 -1.31 -1.25 -1.27 -0.77 -0.85 -0.79 -0.87 -1.24 -1.61 -2.24 -2.74 -2.97 -3.04 -2.95 -2.95 -2.81
EBITDA
-43.84M -42.21M -35.98M -38.44M -36.07M -32.85M -31.26M -24.99M -25.65M -36.24M -51.03M -68.21M -83.05M -88.57M -89.97M -86.98M -87.22M -83.72M
EBIT
-31.59M -40.43M -36.17M -38.91M -36.46M -33.2M -31.58M -25.05M -25.75M -36.43M -51.23M -68.46M -83.34M -88.87M -90.32M -85.58M -85.82M -82.3M
Depreciation & Amortization
134K 178K 186K 474K 388K 345K 322K 60K 100K 183K 204K 246K 293K 296K 344K 345K 342K 335K